Trial Profile

Clinical study of SZN 8143

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SZN 8143 (Primary)
Indications Age-related macular degeneration; Diabetic macular oedema; Retinal oedema
Focus Adverse reactions; Pharmacokinetics

15 May 2025 New trial record
09 May 2025 According to Surrozen media release, Surrozen expects to file an Investigational New Drug (IND) application and commence clinical studies for SZN-8141 in 2026. The Food and Drug Administration clearance of this IND application would trigger funding of the $98.6 million private placement tranche which is expected to fund operations through efficacy, safety and tolerability studies for SZN-8141 and SZN-8143.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com